Back


14/11/2017
Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand’s long-acting GLP-2 analog glepaglutide
Zealand Pharma announces that all subjects have been enrolled and dosed in a clinical trial with glepaglutide under an investigational new drug application (IND) for the treatment of short bowel syndrome (SBS). Following positive results from a Phase 2 trial in June 2017 indicating a longer than expected [...]

Download the pdf file





X

X